source
- Pfizer and Amgen target GLP-1 weight-loss market to rival Novo Nordisk and Eli LillyThe STATus Report video hosted by Alex Hogan discusses the growing GLP-1 weight-loss drug market. Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound have been on the market for a few years and are pop…
- Eli Lilly stops 340B discounts for dozens of hospitals that did not submit claims dataEli Lilly has begun removing the federally mandated 340B price discounts for a few dozen hospitals that have not provided the required claims data. The company said the step follows a warning it is…